Global Competition Review reported on the Federal Trade Commission’s clearance of S&C client Amgen’s pending $27.8 billion acquisition of Horizon Therapeutics after the parties entered into a settlement involving Horizon’s rare disease treatments. The S&C team representing Amgen included Michael Rosenthal, Renata Hesse, Samantha Hynes, Marielena Doeding and Kolja Ortmann.
For further information, please read “FTC Settles Amgen/Horizon Challenge.”
Subscribe to stay current on S&C Insights.
Sending an e-mail through this web site does not create an attorney-client relationship. You should not send us any information through this web site that you would want treated confidentially.